Sudeep Pharma Ltd
Sudeep Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28. FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals.
From Sudeep Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28.
- Specialty Ingredients segment forecasted to continue similar growth as in the past 2-3 years, maintaining strong momentum.
- Bisglycinate product category projected to become a sizable revenue contributor starting FY28.
- With the greenfield facility operational, pharma food nutrition volumes have grown over 20%, expecting further growth with capacity expansion.
- Battery materials volume is expected to scale up, with a fair assumption of selling around 2,500 metric tons in FY27.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sudeep Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Battery Materials Project at Dahej: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027. Total target capacity up to 100,000 metric tons with approx. INR 600 crores capex planned.
- Greenfield Manufacturing Project: Focused on pharma, food, and nutrition verticals, enhancing capabilities for high-value mineral molecules like glycinate and gluconate. Internal production validation completed; customer qualification ongoing.
- Capex in FY26: INR 127 crores (including INR 34 crores for SAM land, INR 80 crores Greenfield project, INR 13 crores maintenance).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sudeep Pharma has a strong order book with ongoing commercial purchase orders, including approximately 700 metric tons for battery materials received recently.
- The company is engaged with 42 global customers across the cathode, cell, EV, and ESS ecosystem; 22 at lab validation, 14 at pilot scale, and 6 at commercial validation.
- For battery materials, customer engagement and qualification progress are encouraging, with active off-take discussions.
- Specialty ingredients segment has good visibility with approvals from large global customers in encapsulation technology and infant nutrition premix categories.
- The company expects the specialty ingredients segment to maintain its growth momentum in FY27.
2 more points management made on order book & pipeline
Sudeep Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹182 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudeep Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Sudeep Pharma Ltd Q4 FY26 results?
Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28. FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals.
What is Sudeep Pharma Ltd share price analysis?
Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma Ltd planning capital expenditure?
Battery Materials Project at Dahej: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027.
Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.